With Another $17M In Hand, Elevation Looks To Advance Nebulized LAMA For COPD
This article was originally published in The Pink Sheet Daily
Executive Summary
Having unveiled promising Phase IIa data at the European Respiratory Society meeting, the biotech is moving EP-101 into Phase IIb to become the first nebulized LAMA for patients with moderate to severe COPD.